Insider trading

Period: 120 months Stock: DYN + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

293 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

293 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

293 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

293 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
293 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
293 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

293 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
11 Jun 2024
Beskrovnaya Oxana Chief Scientific Officer
Sold at will
$66.94K 2,136 at 31.34
1.4%
Not planned
11 Jun 2024
McNeill Jonathan Chief Business Officer
Sold at will
$57.13K 1,823 at 31.34
1.3%
Not planned
11 Jun 2024
Scalzo Richard William SVP, Head of Finance & Admin.
Sold on a plan
$41.71K 1,331 at 31.34
1.2%
Planned (10b5-1)
10 Jun 2024
HIGH SUSANNA GATTI Chief Operating Officer
Sold on a plan
$2.42M 80,000 at 30.24
34.2%
Planned (10b5-1)
10 Jun 2024
Scalzo Richard William SVP, Head of Finance & Admin.
Sold on a plan
$48.07K 1,590 at 30.23
1.4%
Planned (10b5-1)
20 May 2024
Beskrovnaya Oxana Chief Scientific Officer
Sold on a plan 3×
$1.00M 30,426 at 32.96
16.9%
Planned (10b5-1)
16 May 2024
McNeill Jonathan Chief Business Officer
Sold on a plan 2×
$78.42K 2,774 at 28.27
2.0%
Planned (10b5-1)
16 May 2024
HIGH SUSANNA GATTI Chief Operating Officer
Sold on a plan 2×
$77.40K 2,738 at 28.27
1.7%
Planned (10b5-1)
16 May 2024
Beskrovnaya Oxana Chief Scientific Officer
Sold on a plan 2×
$76.47K 2,705 at 28.27
1.8%
Planned (10b5-1)
16 May 2024
Scalzo Richard William SVP, Head of Finance & Admin.
Sold on a plan 2×
$73.16K 2,588 at 28.27
2.2%
Planned (10b5-1)
16 May 2024
Farwell Wildon Chief Medical Officer
Sold on a plan 2×
$67.31K 2,381 at 28.27
1.6%
Planned (10b5-1)
12 Mar 2024
Farwell Wildon Chief Medical Officer
Sold on a plan
$26.35K 1,030 at 25.58
0.7%
Planned (10b5-1)
11 Mar 2024
Brumm Joshua T CEO & President
Sold on a plan 4×
$1.70M 66,387 at 25.67
11.0%
Planned (10b5-1)
11 Mar 2024
McNeill Jonathan Chief Business Officer
Sold on a plan 2×
$499.84K 19,601 at 25.50
12.3%
Planned (10b5-1)
11 Mar 2024
Scalzo Richard William SVP, Head of Finance & Admin.
Sold on a plan 2×
$67.54K 2,672 at 25.28
2.2%
Planned (10b5-1)
11 Mar 2024
HIGH SUSANNA GATTI Chief Operating Officer
Sold on a plan
$58.90K 2,292 at 25.70
1.4%
Planned (10b5-1)
11 Mar 2024
Beskrovnaya Oxana Chief Scientific Officer
Sold on a plan
$53.48K 2,081 at 25.70
1.3%
Planned (10b5-1)
11 Mar 2024
Farwell Wildon Chief Medical Officer
Sold on a plan
$40.73K 1,585 at 25.70
1.0%
Planned (10b5-1)
8 Mar 2024
Brumm Joshua T CEO & President
Sold on a plan 3×
$9.42M 363,343 at 25.93
39.6%
Planned (10b5-1)
8 Mar 2024
McNeill Jonathan Chief Business Officer
Sold on a plan 3×
$2.36M 90,000 at 26.24
38.9%
Planned (10b5-1)
8 Mar 2024
Scalzo Richard William SVP, Head of Finance & Admin.
Sold on a plan 3×
$2.26M 86,252 at 26.22
41.4%
Planned (10b5-1)
8 Mar 2024
HIGH SUSANNA GATTI Chief Operating Officer
Sold on a plan 2×
$725.34K 27,199 at 26.67
14.6%
Planned (10b5-1)
7 Mar 2024
Farwell Wildon Chief Medical Officer
Sold on a plan 2×
$256.58K 9,921 at 25.86
6.1%
Planned (10b5-1)
7 Mar 2024
Brumm Joshua T CEO & President
Sold on a plan
$234.87K 9,086 at 25.85
1.6%
Planned (10b5-1)
7 Mar 2024
McNeill Jonathan Chief Business Officer
Sold on a plan
$62.92K 2,434 at 25.85
1.7%
Planned (10b5-1)
7 Mar 2024
Beskrovnaya Oxana Chief Scientific Officer
Sold on a plan
$61.34K 2,373 at 25.85
1.5%
Planned (10b5-1)
7 Mar 2024
Scalzo Richard William SVP, Head of Finance & Admin.
Sold on a plan
$58.76K 2,273 at 25.85
1.8%
Planned (10b5-1)
7 Mar 2024
HIGH SUSANNA GATTI Chief Operating Officer
Sold on a plan
$41.13K 1,591 at 25.85
0.8%
Planned (10b5-1)
1 Mar 2024
Brumm Joshua T CEO & President
Sold on a plan 3×
$2.74M 94,480 at 29.04
14.4%
Planned (10b5-1)
1 Mar 2024
Rhodes Jason P Director · indirect
Sold on a plan 2×
$1.40M 46,534 at 30.05
5.2%
Planned (10b5-1)
1 Mar 2024
Sold on a plan
$884.52K 29,435 at 30.05
2.0%
Planned (10b5-1)
1 Mar 2024
McNeill Jonathan Chief Business Officer
Sold on a plan 3×
$694.50K 24,260 at 28.63
14.5%
Planned (10b5-1)
1 Mar 2024
Sold on a plan
$513.82K 17,099 at 30.05
2.0%
Planned (10b5-1)
1 Mar 2024
Scalzo Richard William SVP, Head of Finance & Admin.
Sold on a plan 2×
$263.00K 9,311 at 28.25
7.0%
Planned (10b5-1)
29 Feb 2024
Brumm Joshua T CEO & President
Sold on a plan
$151.80K 5,520 at 27.50
1.0%
Planned (10b5-1)
29 Feb 2024
McNeill Jonathan Chief Business Officer
Sold on a plan
$117.37K 4,268 at 27.50
2.9%
Planned (10b5-1)
29 Feb 2024
Scalzo Richard William SVP, Head of Finance & Admin.
Sold on a plan
$94.30K 3,429 at 27.50
2.7%
Planned (10b5-1)
28 Feb 2024
Rhodes Jason P Director · indirect
Sold on a plan 6×
$4.74M 190,920 at 24.84
18.1%
Planned (10b5-1)
28 Feb 2024
Sold on a plan 2×
$3.84M 154,674 at 24.84
2.6%
Planned (10b5-1)
28 Feb 2024
Atlas Venture Fund XI, L.P. 10% owner · indirect
Sold on a plan 4×
$900.23K 36,246 at 24.84
4.0%
Planned (10b5-1)
28 Feb 2024
Farwell Wildon Chief Medical Officer
Sold on a plan
$10.18K 407 at 25.00
0.2%
Planned (10b5-1)
27 Feb 2024
Rhodes Jason P Director · indirect
Sold on a plan 6×
$9.00M 368,699 at 24.41
29.6%
Planned (10b5-1)
27 Feb 2024
Sold on a plan 2×
$7.29M 298,702 at 24.41
4.9%
Planned (10b5-1)
27 Feb 2024
Atlas Venture Fund XI, L.P. 10% owner · indirect
Sold on a plan 4×
$1.71M 69,997 at 24.41
7.4%
Planned (10b5-1)
26 Feb 2024
Rhodes Jason P Director · indirect
Sold on a plan 6×
$5.89M 248,219 at 23.72
21.6%
Planned (10b5-1)
26 Feb 2024
Sold on a plan 2×
$4.77M 201,095 at 23.72
3.2%
Planned (10b5-1)
26 Feb 2024
Atlas Venture Fund XI, L.P. 10% owner · indirect
Sold on a plan 4×
$1.12M 47,124 at 23.72
5.0%
Planned (10b5-1)
23 Feb 2024
Rhodes Jason P Director · indirect
Sold on a plan 3×
$4.47M 196,928 at 22.70
17.6%
Planned (10b5-1)
23 Feb 2024
Sold on a plan
$3.62M 159,542 at 22.70
2.4%
Planned (10b5-1)
23 Feb 2024
Atlas Venture Fund XI, L.P. 10% owner · indirect
Sold on a plan 2×
$848.66K 37,386 at 22.70
3.9%
Planned (10b5-1)
Showing 151–200 of 293. ← Newer Page 4 of 6 Older →